Press Releases

Month Year

Get News Alerts by Email

Oct 26, 2015

Halaven® (eribulin mesylate) Injection Nominated for Best Pharmaceutical Agent of the Year at The Prix Galien USA Awards

Eisai Inc. announced today that Halaven® (eribulin mesylate) Injection has been nominated by the Galien Foundation within the category, "Best Pharmaceutical Agent of the Year" at the ninth annual...
- Photos 1
Oct 26, 2015

Morphotek®, Inc. Presents Preclinical Findings At ESGO 19 On The Potential Immunosuppressive Effects Of The CA125 Tumor Antigen On Farletuzumab, An Investigational Anti-Folate Receptor Alpha Antibody

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has presented preclinical data showing the immunosuppressive effects of the CA125 tumor antigen on the investigational...
- Photos 1
Oct 19, 2015

Results of Hematology/Oncology Pharmacy Association and Eisai Inc. Survey Show 83 Percent of Patients Receiving Chemotherapy May Be Unnecessarily Suffering from Chemotherapy-induced Nausea and Vomiting

Findings suggest need for improved dialogue between patients receiving chemotherapy and their healthcare team, including pharmacists
Oct 16, 2015

Results from Phase 2 Trial Investigating Lenvatinib in Metastatic Renal Cell Carcinoma Published in The Lancet Oncology

Results from an investigational Phase 2 clinical trial evaluating lenvatinib in combination with everolimus and lenvatinib and everolimus alone for the treatment of metastatic renal cell carcinoma...
Oct 15, 2015

Eisai Presents New Analyses of Lenvatinib Data at the International Thyroid Congress (ITC)

Eisai Inc. announced today the presentation of a company-record seven abstracts at the 15th International Thyroid Congress (ITC), highlighting the importance of the Phase 3 SELECT trial of...

Show per page

Open a printable version of this page
Email the URL of this page to a friend